Zantac Contains Cancer-Causing Chemicals


 

Popular heartburn drug put millions at grave risk for developing cancer.


Zantac is one of the nation’s most commonly prescribed heartburn medications. It has been available by prescription and over the counter under the brand name Zantac as well as many generic versions of the active ingredient ranitidine for nearly 40 years. The U.S. Food and Drug Administration has now confirmed these drugs contain dangerous levels of the contaminant N-nitrodimethylamine (NDMA), an impurity known to cause cancer in humans.

If you or a family member developed cancer or liver disease after taking a heartburn medication containing ranitidine, you may be entitled to financial compensation.

Call OPO today at 800-676-5295 to find out more.

START WITH A FREE CONSULTATION






What are the risks from taking Zantac?


Anyone who has taken the drug may have an increased chance of developing several life-threatening conditions.

Zantac contains dangerous amounts of NDMA, which can be extremely toxic to the liver. This carcinogen has been found to cause lung, gastric and colorectal cancers as well as severe liver disease. To make matters worse, the amount of NDMA may become increasingly toxic if the medication is stored at higher-than-normal temperatures, posing even greater risk to the public. In other words, the longer it sits on the shelf – either at the store or at home – the more harmful it becomes.

Has Zantac been recalled?

Yes. The FDA called for the immediate removal of all ranitidine (Zantac) from store shelves just months after launching an investigation into the dangers of the medication. Patients should stop taking and properly dispose of the medication immediately as well as consult a healthcare provider about other treatment options.

How long has Zantac been on the market?

Zantac was first introduced as a prescription-only medication in 1983. Since then, millions of consumers have taken the drug and unknowingly exposed themselves to a cancer-causing chemical.

OPO’s Experienced Attorneys Are Here for You

The attorneys at OPO have a proven history of holding pharmaceutical companies accountable for their actions. Our experience gives you the best chance at winning your case, which means being fairly compensated for your losses.

OPO has successfully fought big pharma on behalf of many clients – here are just a few:

  • $4.85 billion settlement from Merck Pharmaceuticals for victims of the arthritis drug Vioxx.
  • $3.75 billion for victims of the weight-loss drug Fen-phen.
  • $3.4 billion settlement from GlaxoSmithKline for victims of the Type 2 diabetes drug Avandia.
  • $175 million settlement from Parke-David/Warner-Lambert for victims of the diabetes drug Rezulin.
  • $330 million settlement from Pfizer and Wyeth for victims of the hormone replacement therapy (HRT) drug Prempro.
  • $4.85 billion settlement from Merck Pharmaceuticals for victims of the arthritis drug Vioxx.
  • $3.75 billion for victims of the weight-loss drug Fen-phen.
  • $3.4 billion settlement from GlaxoSmithKline for victims of the Type 2 diabetes drug Avandia.
  • $175 million settlement from Parke-David/Warner-Lambert for victims of the diabetes drug Rezulin.
  • $330 million settlement from Pfizer and Wyeth for victims of the hormone replacement therapy (HRT) drug Prempro.

Here’s an overview of Zantac’s history

  • 1983 – GlaxoSmithKline receives FDA approval to sell Zantac in the U.S. to treat ulcers. It was already available in 31 other countries.
  • 1988 – Zantac becomes the world’s best-selling drug and one of the first to top $1 billion in annual sales.
  • 1997 – Glaxo’s patent for the drug’s primary ingredient, ranitidine expires. Other companies begin making and selling generic alternatives.
  • 2004-2017 – An over-the-counter version of Zantac is made approved by the FDA, which leads to several pharmaceutical companies producing generic versions of ranitdine.
  • Late 2019 – The cancer-causing impurity NDMA is discovered in ranitidine products, including Zantac. Several national stores voluntarily stop selling these medications.
  • April 2020 – The FDA recalls all Zantac and its ranitidine counterparts, citing unsafe levels of NDMA.
  • 1983 – GlaxoSmithKline receives FDA approval to sell Zantac in the U.S. to treat ulcers. It was already available in 31 other countries.
  • 1988 – Zantac becomes the world’s best-selling drug and one of the first to top $1 billion in annual sales.
  • 1997 – Glaxo’s patent for the drug’s primary ingredient, ranitidine expires. Other companies begin making and selling generic alternatives.
  • 2004-2017 – An over-the-counter version of Zantac is made approved by the FDA, which leads to several pharmaceutical companies producing generic versions of ranitdine.
  • Late 2019 – The cancer-causing impurity NDMA is discovered in ranitidine products, including Zantac. Several national stores voluntarily stop selling these medications.
  • April 2020 – The FDA recalls all Zantac and its ranitidine counterparts, citing unsafe levels of NDMA.

Who can be part of a Zantac lawsuit?

Anyone who has been harmed by this medication may be entitled to financial compensation.

If you or a loved one developed cancer after taking Zantac or ranitidine, contact OPO today. Our attorneys at OPO are prepared to take legal action on behalf of Zantac users. There is no cost to you to be part of the claim.

Compensation from the claim may include economic damages, such as past and future medical bills and lost wages, as well as losses related to physical and mental pain and suffering. Actual compensation depends upon the specific details of each plaintiff’s case.

Start with a FREE consultation.
Call us at 800.676.5295 or contact us to schedule a meeting to discuss your case with an experienced attorney.